Pathos AI, a clinical-stage AI and technology company based in New York City, announced on October 23, 2026 that it has closed a $237 million Series E financing at a post-money valuation of approximately $3 billion. The round was led by Bristol Myers Squibb, with participation from existing investors.
What the funding is for
According to the company, proceeds will be used to scale its Foundry platform and to accelerate clinical development of its portfolio. Foundry is described as operating through thousands of specialized AI agents that aggregate information for a drug program in real time, synthesizing clinical data, genomics, biological specimen data and the competitive landscape to recommend the next decision for each program.
Four clinical assets in focus
Pathos says it has expanded to four active clinical assets through a series of transactions in recent months. A stated priority is advancing JSKN016, a first-in-class TROP2/HER3 bispecific antibody-drug conjugate, toward registrational studies. The funding will also support pocenbrodib in metastatic castration-resistant prostate cancer and relapsed or refractory multiple myeloma, AZD4241, an ER PROTAC partnered with AstraZeneca, and DO-2, a next-generation MET kinase inhibitor.
What the CEO says
"We are building a platform to systematically improve the probability of success in drug development," said Iker Huerga, CEO of Pathos, in the announcement. He said the capital allows the company to scale its AI engine while steering current programs toward key clinical milestones.
How to read this
Pathos positions Foundry as a way to identify promising clinical assets, calculate continuously updated probabilities of success and steer or drop programs earlier. The company's pipeline spans metastatic castration-resistant prostate cancer, multiple myeloma, MET-altered non-small-cell lung cancer, ER+/HER2- breast cancer and TROP2/HER3-expressing solid tumors. A Series E led by a large pharmaceutical company is a notable signal for the AI drug development category, though the valuation and platform claims come from the company's own announcement and clinical outcomes will take years to test.